AHFS Drug Information 2026

American Hospital Formulary Service Drug Information

AHFS Drug Information 2026

American Hospital Formulary Service Drug Information

563,00 €*

Preise inkl. MwSt., ggf. zzgl. Versandkosten

Auf Wunsch ist ein automatischer Fortsetzungsbezug bei Erscheinen der jeweils neuen Auflage möglich. Bitte schreiben Sie uns in dem Fall eine Nachricht unter "Zusätzliche Informationen" am Ende des Bestellvorganges oder kontaktieren Sie unseren Kundenservice unter Tel. 0711/2582-341

Geplanter Erscheinungstermin: 01/2026

Falls Sie eine Lieferung außerhalb DE, AT oder CH wünschen, nutzen Sie bitte unser Kontaktformular für eine Anfrage.

AHFS Drug Information® 2026 contains the most dependable drug information available—all in one place. It is the most comprehensive evidence-based source of drug information complete with therapeutic guidelines and off-label uses.

With expanded and revised content supported by more than 97,000 references and incorporating the advice of numerous subject matter experts, AHFS DI helps you protect your patients and your practice.

Updates in the new edition:

Clinical perspective sections that include place of therapy discussions and recommendations from therapeutic guidelines

Expanded coverage of specialty medications used to treat a variety of complex, chronic conditions that often require special handling and administration and may require careful oversight to manage severe adverse effects and dosage adjustments

Contemporary topics such as biosimilars, novel orphan drugs, and updated vaccine guidance based on recommendations from the CDC’s Advisory Committee on Immunization Practices (ACIP) and other authoritative organizations

Essential drug information content for patient safety including FDA Medwatch alerts, Standardize4Safety concentrations for IV and oral liquid medications, ISMP recommendations, REMS data, BEERS criteria, boxed warnings, and focused updates based on FDA safety findings

Pharmacogenomic considerations in drug dosing and selection

Expanded content on new and emerging gene and cellular therapies

Class-wide revisions to standard and established therapies for common disease states including hypertension and diabetes

Expanded content on off-label uses, real world data, and long-term clinical data

New content on new molecular entities (NMEs) and biologic approvals

New oncology off-label determinations based on reviews by the AHFS Oncology Expert Committee

ISBN 978-1-58528-777-2
Medientyp Buch - Kartoniert
Auflage 1.
Copyrightjahr 2026
Verlag American Society of Health-System-Pharmacists
Umfang 3504 Seiten
Format 31,7 x 24,7 cm
Sprache Englisch